Form 4: United Therapeutics CEO Trades Shares

Martine A. Rothblatt, Chairperson & CEO of United Therapeutics Corp., reported transactions involving common stock and stock options on June 22, 2026, executed under a 10b5-1 trading plan.

Summary

• Martine A. Rothblatt, Chairperson & CEO of United Therapeutics Corp., engaged in several transactions involving the company's common stock and stock options on June 22, 2026.
• These transactions were conducted under a pre-arranged Rule 10b5-1 trading plan adopted on November 7, 2025.
• The plan is set to continue until the exercise of 1,734,410 stock options, all expiring on March 15, 2027, or until December 31, 2026, whichever comes first.
• Transactions included the exercise of stock options and the subsequent sale of common stock at various prices.
• Rothblatt's beneficial ownership includes direct holdings and indirect holdings through trusts and by spouse.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this filing as neutral to slightly negative due to the significant volume of stock sales by the CEO, despite being conducted under a 10b5-1 plan.

Positives

• The transactions were executed under a Rule 10b5-1 trading plan, indicating a pre-determined and structured approach to stock sales, which can mitigate insider trading concerns.
• The plan allows for continued option exercise and potential future sales, suggesting ongoing confidence in the company's stock value.

Negatives

• Significant sales of common stock by the CEO, totaling thousands of shares across multiple transactions, could be interpreted negatively by the market.
• The weighted average sale price for some transactions was as high as $539.9008, indicating sales at a substantial valuation.

Risks

• The ongoing 10b5-1 plan involves the sale of a large number of shares, which could put downward pressure on the stock price if executed rapidly or if market sentiment shifts.
• The expiration of stock options on March 15, 2027, creates a timeframe for the plan's execution, potentially leading to concentrated selling activity.

Future Outlook

The 10b5-1 trading plan is active and will continue until December 31, 2026, or until 1,734,410 stock options are exercised, whichever occurs first. This indicates ongoing potential for stock transactions by the reporting person.

Management Comments

• The exercise of stock options and sale of resulting shares were pursuant to a pre-arranged 10b5-1 trading plan.
• The reporting person undertakes to provide full information regarding the number of shares and prices at which transactions were effected upon request.

Industry Context

StockSavvy.ai notes that insider selling, even under a 10b5-1 plan, can sometimes be perceived negatively by the market, especially when executed by a CEO. However, the existence of the plan itself is designed to provide a structured and defensible method for such transactions, aligning with regulatory expectations.

Stakeholder Impact

• Shareholders may view the CEO's stock sales with caution, potentially impacting short-term stock price sentiment.
• Employees holding stock options may be influenced by the CEO's strategy regarding option exercise and sale.

Next Steps

• Continued execution of the 10b5-1 trading plan until its termination conditions are met.
• Potential further filings on Form 4 to report subsequent transactions.

Key Dates

Recommendation

The filing details routine stock transactions by the CEO under a pre-established 10b5-1 plan. While significant sales can create short-term negative sentiment, the structured nature of the plan suggests it's a planned liquidity event rather than a reflection of negative company outlook. Therefore, a 'hold' recommendation is appropriate, pending further fundamental analysis of United Therapeutics' business performance.

Keywords

United Therapeutics, UTHR, Form 4, Insider Trading, Stock Options, 10b5-1 Plan, Martine Rothblatt, CEO, Beneficial Ownership, Stock Sale